Biochemical Engineering Special Interest Group
biological engineering professionals
23 October 2017

AstraZeneca helps ADCT to fund anticancer ADCs to pivotal data

ADC Therapeutics has raised $200 million with participation from AZ, bringing its total haul up to $455 million. The antibody-drug conjugate (ADC) specialist will use the money to take its two lead hematological cancer assets through registrational trials. Lausanne, Switzerland-based ADCT is developing ADCs that combine monoclonal antibodies with pyrrolobenzodiazepine (PBD)-based warheads. Source: FierceBiotech 23/10/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).